Zai Lab Ltd.

China’s retaliatory tariffs mean the option of manufacturing US-originated drugs in China is making more sense than ever, at least to some local partners of US pharmaceutical companies. China imposed

Taiho Pharmaceuticals said on 17 March that it will spend $400m up front and up to $740m in milestone payments to expand its cancer drug development pipeline through the acquisition of antibody-drug c

“Either for young biotech or established pharma companies in China, a combination of innovation and globalization is the trend,” Shan Jiang, chief technology officer at Hansoh Pharmaceutical, told the

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Regenxbio Calls On Nippon Shinyaku To